ESC 2024 - "The study met all the 10 endpoints", says Marianna Fontana. She explains what the primary and secondary endpoints were of the HELIOS-B study, in which the efffect of vutrisiran was evaluated in patients with ATTR-CM, who were on or off background therapy.
Remarkable results in phase 3 study with vutrisiran in patients with ATTR-CM
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Educational information
This video was recorded during the ESC Congress 2024 in London, UK.
Faculty
Marianna Fontana is the Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, UK.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 30 August 2024
Recommended
Details
Presenters
Overview
ESC 2024 - "The study met all the 10 endpoints", says Marianna Fontana. She explains what the primary and secondary endpoints were of the HELIOS-B study, in which the efffect of vutrisiran was evaluated in patients with ATTR-CM, who were on or off background therapy.
Educational information
This video was recorded during the ESC Congress 2024 in London, UK.
Faculty
Marianna Fontana is the Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, UK.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 30 August 2024
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
0.50 credits
<p>IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue</p>
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
0.25 credits
<p>IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy</p>
CME/CE
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
0.25 credits
<p>IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis</p>
CME/CE
Updates From the 7th World Symposium Task Force
1.00 credits
<p><span data-contrast="auto" xml:lang="EN-US">Updates From the 7th World Symposium Task Force</span><span data-ccp-props='{"201341983":0,"335559738":210,"335559739":210,"335559740":240}'> </span></p>
Project Oncology®
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
<p>HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)</p>
CME/CE
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
1.00 credits
<p>Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers</p>
CME/CE
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
<p>FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure</p>
MinuteCE®
Second-line Chemotherapy Options in Metastatic PDAC
0.25 credits
<p>Second-line Chemotherapy Options in Metastatic PDAC</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?